Cover Image
市場調查報告書

Resverlogix Corp.:產品平台分析

Resverlogix Corp. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256030
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Resverlogix Corp.:產品平台分析 Resverlogix Corp. - Product Pipeline Review - 2015
出版日期: 2015年09月23日 內容資訊: 英文 32 Pages
簡介

Resverlogix Corp.是表觀遺傳學(後生遺傳學)企業,正在開發心血管疾病,真性糖尿病,老年癡呆症,末稍血管病,慢性腎臟病的治療藥。

本報告提供Resverlogix Corp.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Resverlogix Corp.的基本資料

Resverlogix Corp.概要

  • 主要資訊
  • 企業資料

Resverlogix Corp.:R&D概要

  • 主要的治療範圍

Resverlogix Corp.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Resverlogix Corp.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式
  • 開發階段不明的產品/聯合治療模式

Resverlogix Corp.:藥物簡介

  • apabetalone
  • RVX-2135
  • RVX-297
  • 老年癡呆症的ApoA-I為目標的小分子

Resverlogix Corp.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Resverlogix Corp.:最近的開發平台趨勢

Resverlogix Corp.:暫停中的計劃

Resverlogix Corp.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07592CDB

Summary

Global Markets Direct's, 'Resverlogix Corp. - Product Pipeline Review - 2015', provides an overview of the Resverlogix Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Resverlogix Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Resverlogix Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Resverlogix Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Resverlogix Corp.'s pipeline products

Reasons to buy

  • Evaluate Resverlogix Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Resverlogix Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Resverlogix Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Resverlogix Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Resverlogix Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Resverlogix Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Resverlogix Corp. Snapshot
    • Resverlogix Corp. Overview
    • Key Information
    • Key Facts
  • Resverlogix Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Resverlogix Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Resverlogix Corp. - Pipeline Products Glance
    • Resverlogix Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Resverlogix Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Resverlogix Corp. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Resverlogix Corp. - Drug Profiles
    • apabetalone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RVX-2135
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RVX-297
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate ApoA-I for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Resverlogix Corp. - Pipeline Analysis
    • Resverlogix Corp. - Pipeline Products by Target
    • Resverlogix Corp. - Pipeline Products by Route of Administration
    • Resverlogix Corp. - Pipeline Products by Molecule Type
    • Resverlogix Corp. - Pipeline Products by Mechanism of Action
  • Resverlogix Corp. - Recent Pipeline Updates
  • Resverlogix Corp. - Dormant Projects
  • Resverlogix Corp. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Resverlogix Corp., Key Information
  • Resverlogix Corp., Key Facts
  • Resverlogix Corp. - Pipeline by Indication, 2015
  • Resverlogix Corp. - Pipeline by Stage of Development, 2015
  • Resverlogix Corp. - Monotherapy Products in Pipeline, 2015
  • Resverlogix Corp. - Phase II, 2015
  • Resverlogix Corp. - Preclinical, 2015
  • Resverlogix Corp. - Discovery, 2015
  • Resverlogix Corp. - Unknown, 2015
  • Resverlogix Corp. - Pipeline by Target, 2015
  • Resverlogix Corp. - Pipeline by Route of Administration, 2015
  • Resverlogix Corp. - Pipeline by Molecule Type, 2015
  • Resverlogix Corp. - Pipeline Products by Mechanism of Action, 2015
  • Resverlogix Corp. - Recent Pipeline Updates, 2015
  • Resverlogix Corp. - Dormant Developmental Projects,2015
  • Resverlogix Corp., Other Locations

List of Figures

  • Resverlogix Corp. - Pipeline by Top 10 Indication, 2015
  • Resverlogix Corp. - Pipeline by Stage of Development, 2015
  • Resverlogix Corp. - Monotherapy Products in Pipeline, 2015
  • Resverlogix Corp. - Pipeline by Top 10 Target, 2015
  • Resverlogix Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Resverlogix Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Resverlogix Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top